An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

AstraZeneca Pharma India reported a 27% decline in net profit for Q2 2024, amounting to Rs 38 crore. This is a drop from Rs ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab ... Price ...

Additionally, AstraZeneca increased its guidance for the fiscal year ... In another report released today, Barclays also maintained a Buy rating on the stock with a £140.00 price target. TipRanks ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China.

Shares of AstraZeneca PLC AZN inched up 0.05% to £99.90 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 1.22% to 8,025.77.

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

The data showed that Koselugo met its primary endpoint, demonstrating a statistically significant and clinically meaningful ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total ...

The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...